These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20832214)

  • 21. Tenofovir-induced renal tubular dysfunction presenting with hypocalcaemia.
    Williams J; Chadwick DR
    J Infect; 2006 Apr; 52(4):e107-8. PubMed ID: 16125779
    [No Abstract]   [Full Text] [Related]  

  • 22. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
    Chetchotisakd P
    Expert Rev Anti Infect Ther; 2009 Sep; 7(7):801-5. PubMed ID: 19735222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elvucitabine data released at CROI.
    AIDS Patient Care STDS; 2010 Mar; 24(3):198. PubMed ID: 20235383
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
    Elzi L; Marzolini C; Furrer H; Ledergerber B; Cavassini M; Hirschel B; Vernazza P; Bernasconi E; Weber R; Battegay M;
    Arch Intern Med; 2010 Jan; 170(1):57-65. PubMed ID: 20065200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An unrecognised case of tenofovir-associated Fanconi syndrome.
    Gracey DM; Fernando M; Ziegler J; White CP; Post JJ
    Med J Aust; 2012 Feb; 196():111-2. PubMed ID: 22304601
    [No Abstract]   [Full Text] [Related]  

  • 26. [5 years' data are convincing. Lopinavir as primary therapy is effective and safe in the long term].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():92. PubMed ID: 15373069
    [No Abstract]   [Full Text] [Related]  

  • 27. Tenofovir induced Fanconi syndrome: a possible pharmacokinetic interaction.
    Kapadia J; Shah S; Desai C; Desai M; Patel S; Shah AN; Dikshit RK
    Indian J Pharmacol; 2013; 45(2):191-2. PubMed ID: 23716900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [3 years' data of tenofovir. Confirmed as a valuable building block].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():30-1. PubMed ID: 15373042
    [No Abstract]   [Full Text] [Related]  

  • 29. Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
    Prescrire Int; 2009 Jun; 18(101):105. PubMed ID: 19637416
    [No Abstract]   [Full Text] [Related]  

  • 30. Incidence of proximal renal tubular dysfunction in patients on tenofovir disoproxil fumarate.
    Quinn KJ; Emerson CR; Dinsmore WW; Donnelly CM
    Int J STD AIDS; 2010 Feb; 21(2):150-1. PubMed ID: 20090006
    [No Abstract]   [Full Text] [Related]  

  • 31. [Regimen simplification: lopinavir/ritonavir with or without efavirenz].
    Pacios E
    Enferm Infecc Microbiol Clin; 2009 Nov; 27(9):553; author reply 553-4. PubMed ID: 19716632
    [No Abstract]   [Full Text] [Related]  

  • 32. Bilateral pathologic hip fractures associated with antiretroviral therapy: a case report.
    Rebolledo BJ; Unnanuntana A; Lane JM
    J Bone Joint Surg Am; 2011 Jul; 93(14):e78. PubMed ID: 21792481
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.
    Puthanakit T; van der Lugt J; Bunupuradah T; Ananworanich J; Gorowara M; Phasomsap C; Jupimai T; Boonrak P; Pancharoen C; Burger D; Ruxrungtham K
    J Antimicrob Chemother; 2009 Nov; 64(5):1080-6. PubMed ID: 19729375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy and tolerance of tenofovir-lamivudine-efavirenz combination in HIV-1 patients in Fann Teaching Hospital in Dakar].
    Diop SA; Fortes-Déguénonvo L; Seydi M; Dieng AB; Basse CD; Manga NM; Dia NM; Ndaw G; Ndour CT; Soumaré M; Diop BM; Sow PS
    Bull Soc Pathol Exot; 2013 Feb; 106(1):22-6. PubMed ID: 23247755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months.
    Boothby M; McGee KC; Tomlinson JW; Gathercole LL; McTernan PG; Shojaee-Moradie F; Umpleby AM; Nightingale P; Shahmanesh M
    Antivir Ther; 2009; 14(8):1089-100. PubMed ID: 20032539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
    Lathouwers E; De Meyer S; Dierynck I; Van de Casteele T; Lavreys L; de Béthune MP; Picchio G
    Antivir Ther; 2011; 16(1):99-108. PubMed ID: 21311113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tenofovir-induced Fanconi syndrome and osteomalacia in two HIV-infected patients: role of intracellular tenofovir diphosphate levels and review of the literature.
    Haverkort ME; van der Spek BW; Lips P; Slieker WA; ter Heine R; Huitema AD; Bronsveld W
    Scand J Infect Dis; 2011 Oct; 43(10):821-6. PubMed ID: 21563880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml.
    Nishijima T; Komatsu H; Teruya K; Tanuma J; Tsukada K; Gatanaga H; Kikuchi Y; Oka S
    AIDS; 2013 Mar; 27(5):839-42. PubMed ID: 23719354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early virological failure with a combination of tenofovir, didanosine and efavirenz.
    Podzamczer D; Ferrer E; Gatell JM; Niubo J; Dalmau D; Leon A; Knobel H; Polo C; Iniguez D; Ruiz I
    Antivir Ther; 2005; 10(1):171-7. PubMed ID: 15751775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toward a pharmacogenetic understanding of nucleotide and nucleoside analogue toxicity.
    Hulgan T; Haas DW
    J Infect Dis; 2006 Dec; 194(11):1471-4. PubMed ID: 17083029
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.